FRMD3

Across TCGA pan-cancer cohorts, FRMD3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FRMD3 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FRMD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FRMD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

GBM, BRCA, and PRAD are the cancer types where FRMD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.020	0.416	<.001	12	view →
BRCA	OS	Median	III,IV	0.314	0.834	.006	12	view →
PRAD	DFS	Median	All	0.113	0.776	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.922	0.482	.036	4	view →
SARC	DFS	Median	All	0.098	0.591	.010	3	view →
LGG	OS	Median	All	0.324	0.799	.018	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FRMD3–GBM (OS)

Open the GBM breakdown →